Want to see EBS full AI Analyst Report?
Total Valuation
Emergent Biosolutions has a market cap or net worth of $248.16M. The enterprise value is $879.71.
Market Cap$248.16M
Enterprise Value$879.71
Share Statistics
Emergent Biosolutions has 51,273,335 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,273,335
Owned by Insiders5.35%
Owned by Institutions6.37%
Financial Efficiency
Emergent Biosolutions’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 5.90%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)5.90%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee825.44K
Profits Per Employee58.44K
Employee Count900
Asset Turnover0.56
Inventory Turnover1.14
Valuation Ratios
The current PE Ratio of Emergent Biosolutions is ―. Emergent Biosolutions’s PEG ratio is -0.10.
PE Ratio―
PS Ratio0.89
PB Ratio1.27
Price to Fair Value1.27
Price to FCF4.22
Price to Operating Cash Flow9.08
PEG Ratio-0.10
Income Statement
In the last 12 months, Emergent Biosolutions had revenue of 742.90M and earned 52.60M in profits. Earnings per share was 0.98.
Revenue742.90M
Gross Profit350.60M
Operating Income110.20M
Pretax Income82.80M
Net Income52.60M
EBITDA240.40M
Earnings Per Share (EPS)0.98
Cash Flow
In the last 12 months, operating cash flow was 25.40M and capital expenditures -11.80M, giving a free cash flow of 13.60M billion.
Operating Cash Flow25.40M
Free Cash Flow13.60M
Free Cash Flow per Share0.27
Dividends & Yields
Emergent Biosolutions pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.42
52-Week Price Change-45.22%
50-Day Moving Average7.77
200-Day Moving Average9.51
Relative Strength Index (RSI)16.18
Average Volume (3m)864.70K
Important Dates
Emergent Biosolutions upcoming earnings date is Nov 11, 2026, TBA (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 11, 2026
Ex-Dividend Date―
Financial Position
Emergent Biosolutions as a current ratio of 5.01, with Debt / Equity ratio of 170.42%
Current Ratio5.01
Quick Ratio2.41
Debt to Market Cap0.87
Net Debt to EBITDA1.53
Interest Coverage Ratio1.86
Taxes
In the past 12 months, Emergent Biosolutions has paid 30.20M in taxes.
Income Tax30.20M
Effective Tax Rate0.36
Enterprise Valuation
Emergent Biosolutions EV to EBITDA ratio is 4.28, with an EV/FCF ratio of 6.56.
EV to Sales1.38
EV to EBITDA4.28
EV to Free Cash Flow6.56
EV to Operating Cash Flow6.03
Balance Sheet
Emergent Biosolutions has $139.70M in cash and marketable securities with $581.80M in debt, giving a net cash position of -$442.10M billion.
Cash & Marketable Securities$139.70M
Total Debt$581.80M
Net Cash-$442.10M
Net Cash Per Share-$8.62
Tangible Book Value Per Share$1.61
Margins
Gross margin is 49.40%, with operating margin of 14.83%, and net profit margin of 7.08%.
Gross Margin49.40%
Operating Margin14.83%
Pretax Margin11.15%
Net Profit Margin7.08%
EBITDA Margin32.36%
EBIT Margin19.13%
Analyst Forecast
The average price target for Emergent Biosolutions is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside37.74% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast-9.56%
EPS Growth Forecast-231.68%